The present disclosure generally relates to film-forming compositions and capsules formed from such compositions, including processes for using such compositions to make capsules. In some embodiments, the film-forming compositions are free of animal products and carrageenan.

The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.

The present disclosure is related to a liquid viscoelastic swallowing aid formulated to promote safe swallowing of Solid Oral Dosage Forms (SODF), e.g., tablets and/or capsules, in a patient in need thereof, and uses of such a liquid viscoelastic swallowing aid.

Compositions include an extended release fat-soluble active composition. In certain aspects, the extended release fat-soluble active composition includes an extended release bead multiparticulate comprising a fat-soluble active. In other aspects, the extended release fat-soluble active composition includes an extended release lipid multiparticulate comprising a fat-soluble active.

A method of improving microbiome within an animal can include administering to the animal a composition containing a probiotic and psyllium. The probiotic has at least one of any suitable strain or subspecies of Enterococcus. Compositions containing a probiotic and psyllium are also provided herein.

A composition suitable as coating or binding agent for pharmaceutically, nutraceutically or cosmetically active ingredients includes: a) at least one (meth)acrylate copolymer a), including polymerized units of 5-25% by weight of methacrylic acid and 75-95% by weight of C.sub.1-4-alkylesters of methacrylic acid and/or C.sub.1-4-alkylesters of acrylic acid, and b) 1-25% by weight, based on the total weight of at least one (meth)acrylate copolymer a), of an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid having 10 to 30 carbon atoms, and c) or d) or both c) and d) c) 2-25% by weight, based on the total weight of a), of at least one compound selected from glyceryl tristearate, hydroxypropyl methylcellulose, glyceryl behenate, and glyceryl monostearate and/or d) 25-90% by weight, based on the total weight of a), of at least one selected from talc, rice hulls in powder form, magnesium stearate, corn starch, and microcrystalline cellulose.

Provided herein are compositions and methods useful in the treatment of hearing loss diseases, such as by correction of mutations in genes associated with hearing.

Disclosed herein are compositions comprising topiramate and bioxome, redoxome, HA, extracellular vesicles (EV), or PRP extracellular vesicles, or any combination thereof. Further provided herein are methods for treating dermatological conditions, and methods for testing said compositions.

The present invention relates to: a pharmaceutical composition comprising extracellular vesicles transformed with a recombinant expression vector in which a gene expressing a ligand that binds to receptors of colorectal cancer cells is inserted into a gene that is expressed in extracellular vesicles of stem cells; and a method for preparing an expression vector for preventing or treating colorectal cancer. The present invention has an advantage in that exosomes, as extracellular vesicles, can be utilized as a drug delivery material and target and specifically act on colorectal cancer by selectively binding to colorectal cancer cells which are target cells.

The invention provides an agent delivery system comprising an agent preparation encapsulated within a membrane composition. The invention further provides a membrane composition comprising a ganglioside and lipid for encapsulating agents, and processes for preparing the membrane compositions. The invention further provides agent preparations encapsulated within the membrane compositions, including a plurality of individual particles wherein each particle contains agent preparation individually encapsulated within membrane composition. The invention also provides processes for preparing encapsulated agent preparations or individual particles of encapsulated agent preparations. The agents may be biologically active including hydrophilic, hydrophobic, small molecule or large molecule therapeutic agents. The invention further provides pharmaceutical compositions comprising encapsulated agent preparations or individual particles of encapsulated agent preparations. The invention further provides methods for delivery of the encapsulated agent preparations or individual particles of encapsulated agent preparations to a subject, including oral delivery of large molecule therapeutic agents to the lymphatic system, blood circulatory system, and/or targeted delivery to cells, tissues or organs.